[ad_1] MENLO PARK, Calif., Dec. 15, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present […]
Tag: GRAIL
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
[ad_1] More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings PATHFINDER 2 is the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Study in […]
GRAIL Reports Third Quarter 2024 Financial Results
[ad_1] Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif., Nov. 12, 2024 /PRNewswire/ — GRAIL, […]
GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)
[ad_1] MENLO PARK, Calif., Aug. 30, 2024 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards […]
